Moderna Therapeutics pioneered mRNA technology to develop vaccines and therapies that scale quickly, reduce risk, and adapt to different targets. So far, its efforts have paid off, as shown by the record-setting development timelines seen with Spikevax, its mRNA vaccine for COVID-19. While Moderna’s work on Spikevax is critical, it is only one of the company’s global initiatives. Moderna is investing in overall R&D agility and nurturing its growing pipeline, which currently consists of 40 developmental vaccines and therapies for rare and infectious diseases and oncology. Clear and consistent guidance from senior management and a mantra of “scale and collaborate” have helped them prioritize the projects that will bring the most value.

Join for free to read